Combining Esketamine and Prolonged Exposure Treatment for PTSD (Post Traumatic Stress Disorder)
This open-label, proof-of-concept trial (n=8) will investigate the feasibility and effects of combining intranasal esketamine (28-84mg) with Prolonged Exposure (PE) therapy for the treatment of post-traumatic stress disorder (PTSD). Participants will receive 10 sessions of PE in a massed format over two weeks, alongside esketamine administered six times (three times per week) approximately one hour after specific PE sessions.
Details
An early phase I/II, open-label, single-group pilot to evaluate feasibility, acceptability, and preliminary clinical effects of intranasal esketamine combined with massed Prolonged Exposure for individuals with PTSD.
Participants receive 10 individual PE sessions over 2 weeks with intranasal esketamine administered six times (~1 hour after selected PE sessions); outcomes include PTSD symptom change, safety/tolerability, and feasibility metrics.